HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Tempus Unveils Latest Research at AACR: Analyzing Multimodal Data for Potential Therapeutic Paths with HER2-Directed Antibody-Drug Conjugates Across Various Tumor Types

NextEdge Admin

06 Apr 2024

2 min 28 sec

Tempus, a leader in artificial intelligence and precision medicine, will unveil groundbreaking data in collaboration with Pfizer at the AACR 2024 Annual Meeting. Their abstract, titled “Analysis of HER2 prevalence by RNA expression across solid tumors,” investigates HER2 protein levels and ERBB2 mRNA levels in locally advanced/metastatic (LA/m) breast and gastric cancer patients. Remarkably, they found that RNA expression in various solid tumors, beyond breast and gastric cancer, may correspond to HER2 protein levels, indicating potential therapeutic opportunities for HER2-directed antibody-drug conjugates.

Seagen, acquired by Pfizer in December 2023, previously engaged Tempus in 2022 to explore patient cohorts with HER2 RNA expression. Tempus’ computational and real-world evidence teams contributed insights on HER2 expression prevalence in select solid tumors. Pfizer leverages Tempus’ extensive multimodal database to advance its HEOR and Translational Science team’s research.

Ryan Fukushima, Tempus’ Chief Operating Officer, expressed gratitude for the collaboration, highlighting the significance of expanding understanding regarding HER2 expression in solid tumors beyond breast and gastric cancers. For this study, Tempus analyzed 4,500 de-identified records from its database to support Pfizer’s research endeavors.

Tempus pioneers precision medicine by applying artificial intelligence practically in healthcare. With one of the world’s largest multimodal data libraries and an accessible operating system, Tempus provides AI-enabled precision medicine solutions to physicians, facilitating personalized patient care. Their platform also supports the discovery, development, and delivery of optimal therapeutics, aiming for patients to benefit from collective treatment experiences. As Tempus gathers more data, their tools continuously learn, enhancing patient outcomes.